-
Je něco špatně v tomto záznamu ?
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline
I. Vergote, I. Ray-Coquard, D. Lorusso, A. Oaknin, D. Cibula, T. Van Gorp
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu přehledy, časopisecké články
- MeSH
- imunokonjugáty * MeSH
- imunoterapie MeSH
- lidé MeSH
- nádory děložního čípku * farmakoterapie patologie MeSH
- paclitaxel terapeutické užití MeSH
- testované léky farmakologie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
INTRODUCTION: Recurrent or primary advanced metastatic cervical cancer (R/M CC) has a poor prognosis with a 5-year-survival rate of 16.5%, demanding novel and improved therapies for the treatment of these patients. The first-line standard of care for R/M CC now benefits from the addition of the immune checkpoint inhibitor, pembrolizumab, to platinum-based chemotherapy with paclitaxel and bevacizumab. Additionally, new options for second-line treatment have become available in recent years. AREAS COVERED: Here, we review current investigational drugs and discuss their relative targets, efficacies, and potential within the R/M CC treatment landscape. This review will focus on recently published data and key ongoing clinical trials in patients with R/M CC, covering multiple modes of action, including immunotherapies, antibody-drug conjugates, and tyrosine kinase inhibitors. We searched clinicaltrials.gov for ongoing trials and pubmed.ncbi.nih.gov for recently published trial data, as well as recent years' proceedings from the annual conferences of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Society of Gynaecological Oncology (ESGO), and the International Gynecologic Cancer Society (IGCS). EXPERT OPINION: Therapeutics currently attracting attention include novel immune checkpoint inhibitors, therapeutic vaccinations, antibody-drug conjugates, such as tisotumab vedotin, tyrosine kinase inhibitors targeting HER2, and multitarget synergistic combinations.
Belgium and Luxembourg Gynaecological Oncology Group Leuven Belgium European Union
Central and Eastern European Gynecologic Oncology Group Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003924
- 003
- CZ-PrNML
- 005
- 20230425140957.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/13543784.2023.2179483 $2 doi
- 035 __
- $a (PubMed)36803278
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vergote, Ignace $u Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium, European Union
- 245 10
- $a Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline / $c I. Vergote, I. Ray-Coquard, D. Lorusso, A. Oaknin, D. Cibula, T. Van Gorp
- 520 9_
- $a INTRODUCTION: Recurrent or primary advanced metastatic cervical cancer (R/M CC) has a poor prognosis with a 5-year-survival rate of 16.5%, demanding novel and improved therapies for the treatment of these patients. The first-line standard of care for R/M CC now benefits from the addition of the immune checkpoint inhibitor, pembrolizumab, to platinum-based chemotherapy with paclitaxel and bevacizumab. Additionally, new options for second-line treatment have become available in recent years. AREAS COVERED: Here, we review current investigational drugs and discuss their relative targets, efficacies, and potential within the R/M CC treatment landscape. This review will focus on recently published data and key ongoing clinical trials in patients with R/M CC, covering multiple modes of action, including immunotherapies, antibody-drug conjugates, and tyrosine kinase inhibitors. We searched clinicaltrials.gov for ongoing trials and pubmed.ncbi.nih.gov for recently published trial data, as well as recent years' proceedings from the annual conferences of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Society of Gynaecological Oncology (ESGO), and the International Gynecologic Cancer Society (IGCS). EXPERT OPINION: Therapeutics currently attracting attention include novel immune checkpoint inhibitors, therapeutic vaccinations, antibody-drug conjugates, such as tisotumab vedotin, tyrosine kinase inhibitors targeting HER2, and multitarget synergistic combinations.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory děložního čípku $x farmakoterapie $x patologie $7 D002583
- 650 _2
- $a testované léky $x farmakologie $x terapeutické užití $7 D015507
- 650 _2
- $a paclitaxel $x terapeutické užití $7 D017239
- 650 _2
- $a imunoterapie $7 D007167
- 650 12
- $a imunokonjugáty $7 D018796
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ray-Coquard, Isabelle $u Medical Oncology Department, Centre Léon Bérard and University Claude Bernard Lyon 1, GINECO, Lyon, France
- 700 1_
- $a Lorusso, Domenica $u Gynecologic Oncology Unit, Catholic University of Sacred Heart and Fondazione Policlinico Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Oaknin, Ana $u Gynecologic Cancer Program, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
- 700 1_
- $a Cibula, David $u Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; Central and Eastern European Gynecologic Oncology Group (CEEGOG), Prague, Czech Republic
- 700 1_
- $a Van Gorp, Toon $u Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium, European Union
- 773 0_
- $w MED00181400 $t Expert opinion on investigational drugs $x 1744-7658 $g Roč. 32, č. 3 (2023), s. 201-211
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36803278 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425140954 $b ABA008
- 999 __
- $a ok $b bmc $g 1924530 $s 1190133
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 32 $c 3 $d 201-211 $e 20230307 $i 1744-7658 $m Expert opinion on investigational drugs $n Expert Opin Investig Drugs $x MED00181400
- LZP __
- $a Pubmed-20230418
